Overview

CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL)

Status:
Completed

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if CD5789 is safe and tolerable when given to patients with early stage CTCL. CD5789 is designed to attach to tumor cells and change their genetic material. This may stop the growth of the tumor cells.

Phase:

Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Galderma R&D

Treatments:

Trifarotene